Patient assessment of lower urinary tract symptoms using the international prostate symptom score following low-dose-rate prostate brachytherapy
To correlate changes in urinary patient-reported outcomes including the International Prostate Symptom Score (IPSS), acute urinary retention and urethral stricture with urethral dose in those treated with low dose rate (LDR) prostate brachytherapy. (Source: Brachytherapy)
Source: Brachytherapy - August 2, 2021 Category: Cancer & Oncology Authors: JC Farris, RT Hughes, CR Steber, TE Craven, BA Frizzell Source Type: research

Outcomes for posterior uveal melanoma: Validation of American Brachytherapy Society Guidelines
To assess outcomes of small and medium choroidal melanoma (less than 5.0 mm in height) following Iodine-125 episcleral brachytherapy. (Source: Brachytherapy)
Source: Brachytherapy - July 23, 2021 Category: Cancer & Oncology Authors: Kyle Meidenbauer, Zachary Richards, Renato J. Yupari, James F. Bena, Allan Wilkinson, John Suh, Arun D. Singh Source Type: research

American Brachytherapy Society (ABS) consensus statement for soft-tissue sarcoma brachytherapy
We present updated guidelines from the American Brachytherapy Society regarding the utilization of brachytherapy in the management of STS. (Source: Brachytherapy)
Source: Brachytherapy - July 21, 2021 Category: Cancer & Oncology Authors: Shauna R. Campbell, Chirag Shah, Jacob G. Scott, Nathan Mesko, Lukas Nystrom, Matthew Kolar, Abel Cordoba Largo, Mitchell Kamrava, Firas Mourtada, Arash O. Naghavi, Louis B. Harrison Source Type: research

Cost-effectivess of SpaceOAR system during prostate cancer radiation therapy: Really helpful or excess of expectations?
Recently Patel AK et al. (1) have retrospective evaluated acute patient-reported bowel quality of life (QOL) and rectal bleeding in prostate cancer patients (69 patients) treated with combination external beam radiation (EBRT), low-dose-rate brachytherapy (LDR-BT), and SpaceOAR (a hydrogel absorbable spacer). They concluded that with combination EBRT, LDR-BT, and SpaceOAR, bowel QOL returned to the baseline 3 months after LDR-BT and a clinically significant rectal bleeding less than 5%. This clinical experience highlights how the use of SpaceOAR system rapidly increasing in recent years. (Source: Brachytherapy)
Source: Brachytherapy - July 19, 2021 Category: Cancer & Oncology Authors: Jacopo Giuliani, Francesco Fiorica Tags: Letter to the Editor Source Type: research

Commissioning of an intra-operative US guided prostate HDR system integrating an EM tracking technology
In this study, the commissioning and performance evaluation of the new real-time prostate high-dose-rate brachytherapy investigational system from Philips Disease Management Solutions integrating EMT was performed before its clinical integration. (Source: Brachytherapy)
Source: Brachytherapy - July 14, 2021 Category: Cancer & Oncology Authors: Marie-Claude Lavall ée, Audrey Cantin, Fanny Monéger, Martine Lefebvre, William Foster, Eric Vigneault, Luc Beaulieu Source Type: research

Radiation dose rate variations in different measurement scenarios after prostate 125I brachytherapy
This study aimed to directly compare different measurement scenarios using a supplemental radiation exposure measurement data set. (Source: Brachytherapy)
Source: Brachytherapy - July 14, 2021 Category: Cancer & Oncology Authors: Takashi Hanada, Atsunori Yorozu, Riki Kikumura, Toshio Ohashi, Naoyuki Shigematsu Source Type: research

Determination of Ir-192 micrselectron-V2 HDR/PDR dwell position reproducibility using a slit camera
To examine the limits of dwell position reproducibility of an ELEKTA microSelectron-V2 HDR/PDR remote afterloader. (Source: Brachytherapy)
Source: Brachytherapy - July 10, 2021 Category: Cancer & Oncology Authors: Don Robinson Source Type: research

Long-term outcomes after enucleation or plaque brachytherapy of choroidal melanomas touching the optic disc
To investigate local and systemic outcomes after enucleation, brachytherapy with ruthenium-106, iodine-125, notched and non-notched plaques and transpupillary thermotherapy (TTT) of choroidal melanomas touching the optic disc. (Source: Brachytherapy)
Source: Brachytherapy - July 9, 2021 Category: Cancer & Oncology Authors: Maria Fili, Melvin Astrahan, Gustav St ålhammar Source Type: research

Impact of the Radiation Oncology Alternative Payment Model on Brachytherapy Reimbursement
The Radiation Oncology Alternative Payment Model (RO Model) will test prospective radiotherapy episode-based payments for 16 common disease sites. We created an automated analytics platform to calculate the impact of the RO Model vs historical fee-for-service episode reimbursements for brachytherapy treatments within five community oncology practices for prostate, uterine, and cervical cancer. (Source: Brachytherapy)
Source: Brachytherapy - July 5, 2021 Category: Cancer & Oncology Authors: Nikhil G. Thaker, Rehman Meghani, Cassandra Wilson, Jody Garey, Philip Nelson, Gautam H. Thaker, Chirag Shah, Peter Orio, Catheryn M. Yashar, Vivek Kavadi Source Type: research

PSA outcomes and late toxicity of single-fraction HDR brachytherapy and LDR brachytherapy as monotherapy in localized prostate cancer: A phase 2 randomized pilot study
To evaluate the PSA outcomes and the late patient's reported health related quality of life (HRQOL) and toxicity after single-fraction High-Dose-Rate brachytherapy (HDRB) and Low-Dose-Rate brachytherapy (LDRB) for prostate cancer. (Source: Brachytherapy)
Source: Brachytherapy - July 5, 2021 Category: Cancer & Oncology Authors: Thomas Reynaud, Lara Hathout, Damien Carignan, Maroie Barkati, Andr é-Guy Martin, William Foster, Frédéric Lacroix, Guila Delouya, Daniel Taussky, Gerard Morton, Eric Vigneault Source Type: research

Acute and late complications and toxicities of skin brachytherapy
Skin cancer is the most prevalent malignancy, and its incidence is rising. Surgery is the primary treatment, however, morbidity of surgical resection in certain parts of the body warrant alternate treatment options such as radiation therapy. Complex topology of the skin can pose a challenge for treatment with photon and electron external beam radiotherapy techniques. Brachytherapy can be an attractive radiotherapy technique for these regions. Furthermore, brachytherapy results in lower dose to the underlying deep organs. (Source: Brachytherapy)
Source: Brachytherapy - July 4, 2021 Category: Cancer & Oncology Authors: Amandeep S. Taggar, Paveen Mann, Alexandra Stewart, Phillip Devlin, Anna Likhacheva Tags: Review Article Source Type: research

Intravascular coronary brachytherapy combined with a drug-coated balloon
Coronary artery disease leads to stenosis of the major cardiac vessels, resulting in ischemia and infarction. Percutaneous intervention (PCI) with balloon angioplasty can re-open stenosed vessels. Drug eluting stents (DES) and intravascular brachytherapy (IVBT) and drug-coated balloons (DCBs) are proven to decrease the likelihood of another restenosis after PCI, but neither is completely effective. Due to the limited long-term effectiveness of IVBT or DCB used separately for salvage PCI, we combined the two in some poor prognosis patients. (Source: Brachytherapy)
Source: Brachytherapy - July 2, 2021 Category: Cancer & Oncology Authors: Kathleen E. Kearney, Kent Wallner, Minsun Kim, Ravi S. Hira, Edward Y. Kim, Kenta Nakamura, Upendra Parvathaneni, Zachary L. Steinberg, James M. McCabe, William L. Lombardi, Mark L. Phillips, Creighton Don Source Type: research

Editorial Board
(Source: Brachytherapy)
Source: Brachytherapy - July 1, 2021 Category: Cancer & Oncology Source Type: research

Masthead
(Source: Brachytherapy)
Source: Brachytherapy - July 1, 2021 Category: Cancer & Oncology Source Type: research

Table of Contents
(Source: Brachytherapy)
Source: Brachytherapy - July 1, 2021 Category: Cancer & Oncology Source Type: research

How to design, fabricate, and validate a customized COMS-style eye plaque: Illustrated with a narrow-slotted plaque example
A customized Collaborative Ocular Melanoma Study (COMS)-style eye plaque may provide superior dosimetric coverage compared with standard models for certain intraocular tumor locations and shapes. This work provides a recipe for developing and validating such customized plaques. (Source: Brachytherapy)
Source: Brachytherapy - June 30, 2021 Category: Cancer & Oncology Authors: Christopher L. Deufel, Lauren A. Dalvin, Jing Qian, Birjoo Vaishnav, Jordan McCauley Cutsinger, Michelle Neben Wittich, Ivy A. Petersen Tags: Technical Note Source Type: research

Comprehensive assessment of the effect of eye plaque tilt on tumor dosimetry
PURPOSE: Tilting of the posterior plaque margin during eye plaque brachytherapy can lead to tumor underdosing and increased risk of local recurrence. We performed a quantitative analysis of the dosimetric effects of plaque tilt as a function of tumor position, basal dimension, height and plaque type using 3D treatment planning software.MATERIALS AND METHODS: Posterior and anterior tumors with largest basal dimensions of 6, 12 and 18 mm and heights of 4, 7 and 10 mm were modeled. Both Eye Physics and COMS plaques were simulated and uniformly loaded. (Source: Brachytherapy)
Source: Brachytherapy - June 28, 2021 Category: Cancer & Oncology Authors: Matthew T. Studenski, Arnold Markoe, Stuart E. Samuels, Zelia M. Correa, Elizabeth Bossart, J. William Harbour Source Type: research

Quantifying clinical severity of physics errors in high-dose rate prostate brachytherapy using simulations
To quantitatively evaluate through automated simulations the clinical significance of potential high-dose rate (HDR) prostate brachytherapy (HDRPB) physics errors selected from our internal failure-modes and effect analysis (FMEA). (Source: Brachytherapy)
Source: Brachytherapy - June 27, 2021 Category: Cancer & Oncology Authors: David Aramburu Nunez, Michael Trager, Joel Beaudry, Gilad N. Cohen, Lawrence T. Dauer, Daniel Gorovets, Nima Hassan Rezaeian, Marisa A. Kollmeier, Brian Leong, Patrick McCann, Matthew Williamson, Michael J. Zelefsky, Antonio L. Damato Source Type: research

Geographic access to brachytherapy services in the United States
Disparities in geographic access to medical care exist in nearly all fields of medicine including radiation oncology. We aim to update knowledge of the geographic distribution of radiation oncologists in the United States. (Source: Brachytherapy)
Source: Brachytherapy - June 18, 2021 Category: Cancer & Oncology Authors: James E Bates, Nikhil G. Thaker, Akash Parekh, Trevor J Royce Source Type: research

In reply to Giuliani et al.
To the Brachytherapy Editorial Office, (Source: Brachytherapy)
Source: Brachytherapy - June 14, 2021 Category: Cancer & Oncology Authors: Ankur K. Patel, Sushil Beriwal Source Type: research

Ten-year treatment complication outcomes of radical prostatectomy vs external beam radiation vs brachytherapy for 1503 patients with intermediate risk prostate cancer
To compare 10-year late complications of radical prostatectomy (RP) versus external-beam-radiation-therapy (EBRT) versus brachytherapy (BT). (Source: Brachytherapy)
Source: Brachytherapy - June 2, 2021 Category: Cancer & Oncology Authors: Barry W. Goy, Raoul Burchette Source Type: research

Adverse events of after-loading high dose rate brachytherapy reported to the United States Food and Drug Administration (FDA)
To provide an assessment of safety regarding high-dose-rate after-loading brachytherapy (HDR-BT) based on adverse events reported to the OpenFDA, an open access database maintained by the United States Food and Drug Administration (FDA). (Source: Brachytherapy)
Source: Brachytherapy - June 2, 2021 Category: Cancer & Oncology Authors: Destie Provenzano, Kevin Rao, Gizem Cifter, Neil Taunk, Benjamin Fischer-Valuck, Alexander Lin, Mehrdad Sarfaraz, Hamid Aghdam, Martin Ojong-Ntui, Murray H. Loew, Sharad Goyal, Yuan James Rao Source Type: research

Virtual reality distraction during uterovaginal brachytherapy applicators ’ removal: A pilot comparative study
To assess the relevance of virtual reality distraction (VR) during uterovaginal brachytherapy applicators ’ removal, as an alternative to nitrous oxide (N2O) conscious sedation, to decrease anxiety and pain perception. (Source: Brachytherapy)
Source: Brachytherapy - May 14, 2021 Category: Cancer & Oncology Authors: Romain Varnier, Odile Bri ère, Thomas Brouillard, Isabelle Martel-Lafay, Anne-Agathe Serre, Audrey Couillet, Gisèle Chvetzoff, Cécile Freulet, Pascal Pommier Source Type: research

Validation of the collapsed cone algorithm for HDR liver brachytherapy against Monte Carlo simulations
To validate the collapsed cone (CC) algorithm against Monte Carlo (MC) simulations for model-based dose calculations in high-dose-rate (HDR) liver brachytherapy. (Source: Brachytherapy)
Source: Brachytherapy - May 14, 2021 Category: Cancer & Oncology Authors: Anna Sophie Duque, Teun van Wagenberg, Max Seidensticker, Florian Streitparth, Franziska Walter, Katia Parodi, Frank Verhaegen, Jens Ricke, Claus Belka, Gabriel Paiva Fonseca, Stefanie Corradini, Guillaume Landry Source Type: research

Characterization of combined intracavitary/interstitial brachytherapy including oblique needles in locally advanced cervix cancer
To characterize and report on dosimetric outcomes of image guided adaptive brachytherapy (IGABT) using intracavitary and interstitial (IC/IS) applicators including oblique needles (O-needles) in locally advanced cervical cancer (LACC). (Source: Brachytherapy)
Source: Brachytherapy - May 14, 2021 Category: Cancer & Oncology Authors: Monica Serban, Lars Fokdal, S øren Kynde Nielsen, Steffen Bjerre Hokland, Anders Traberg Hansen, Harald Spejlborg, Susanne Rylander, Primoz Petric, Jacob Christian Lindegaard, Kari Tanderup Source Type: research

Inter-fractional variation of markers and applicators in single-implant high-dose-rate interstitial brachytherapy for gynecologic malignancies
Implanted fiducial markers are a commonly used tool in delineating the CTV in high-dose-rate interstitial brachytherapy (HDR-ISBT) for gynecologic malignancy, but their reliability in gynacological sites is not well understood. These markers and interstitial applicators can experience interfractional motion due to organ swelling or other anatomical changes. The purpose of this study was to evaluate the spatial variation of these features. (Source: Brachytherapy)
Source: Brachytherapy - May 13, 2021 Category: Cancer & Oncology Authors: Mark Ostyn, Aidan M. Burke, Emma Fields, Dorin Todor Source Type: research

Intraprostatic calcification and biochemical recurrence in men treated with cesium-131 prostate brachytherapy
Baseline intraprostatic calcification (IC) has been shown to be associated with a higher rate of biochemical recurrence (BCR) in men treated with iodine-125 prostate brachytherapy (PB). We evaluated this association in a cohort of men treated with cesium-131 PB. (Source: Brachytherapy)
Source: Brachytherapy - May 13, 2021 Category: Cancer & Oncology Authors: Michael D. Schad, Joshua L. Rodr íguez-López, Ankur K. Patel, Christopher J. Houser, Zachary D. Horne, Ronald M. Benoit, Ryan P. Smith, Sushil Beriwal Tags: GEN Source Type: research

High-dose-rate brachytherapy with surface applicator in penile cancer
An alternative to surgery for penile cancer is radiation therapy which is administered with external beam techniques and/or brachytherapy (BT) either interstitial or using a surface applicator. Here we report our experience in penile cancer patients treated with high-dose-rate (HDR)-BT with the surface technique, analyzing dosimetric parameters and clinical outcomes. (Source: Brachytherapy)
Source: Brachytherapy - May 13, 2021 Category: Cancer & Oncology Authors: Simonetta Saldi, Claudio Zucchetti, Christian Paolo Luca Fulcheri, Stefano Saccia, Emanuele Al ì, Simona Marani, Gianluca Ingrosso, Cynthia Aristei Tags: Technical Note Source Type: research

Prostate brachytherapy in cooperative group clinical trials: What is the best path forward in the radiosurgery era?
A significant criticism of prostate brachytherapy has always been the relative lack of prospective, randomized trials investigating its optimal utilization. This is becoming more apparent in the context of progressive, external beam radiotherapy (EBRT) treatment techniques such as hypofractionation and stereotactic body radiotherapy (SBRT) which have undergone and continue to undergo vigorous clinical investigation (1 –3). Multiple prospective studies, including large-scale, cooperative group clinical trials, continue to accrue and lead to refinement and greater acceptance of SBRT for prostate cancer. (Source: Brachytherapy)
Source: Brachytherapy - May 12, 2021 Category: Cancer & Oncology Authors: Daniel J. Krauss, Peter Rossi Tags: Editorial Source Type: research

Computed tomography guided interstitial percutaneous high-dose-rate brachytherapy in the management of lung malignancies. A review of the literature
A growing number of patients with lung cancer are not amenable to surgery due to their age or comorbidities. For this reason, local ablative techniques have gained increasing interest recently in the management of inoperable lung tumors. High-dose-rate percutaneous interstitial brachytherapy, performed under CT-guidance, is a newer form of brachytherapy and is a highly conformal radiotherapy technique. The aim of this study was to describe this method and review the existing literature. Eight articles comprising 234 patients reported toxicity and clinical outcome. (Source: Brachytherapy)
Source: Brachytherapy - May 10, 2021 Category: Cancer & Oncology Authors: Konstantinos Ferentinos, Efstratios Karagiannis, Iosif Strouthos, Alexis Vrachimis, Paul J Doolan, Nikolaos Zamboglou Source Type: research

Acute and late side-effects after low dose-rate brachytherapy for prostate cancer; incidence, management and technical considerations
To review common reported side effects and complications after primary LDR-BT (monotherapy) and discuss some of the technical aspects that could impact the treatment outcomes. (Source: Brachytherapy)
Source: Brachytherapy - May 7, 2021 Category: Cancer & Oncology Authors: Joelle Helou, Tomer Charas Source Type: research

ABS21 Author Index
(Source: Brachytherapy)
Source: Brachytherapy - May 1, 2021 Category: Cancer & Oncology Source Type: research

PP01 Presentation Time: 10:00 AM
Purpose/Objective(s): There is no standard simulation training geared towards interstitial brachytherapy (IS BT) for gynecologic malignancies. Many residents perform few IS cases during residency. However, IS BT is an integral part of care for locally advanced gynecologic malignancies. We manufactured a low-cost phantom for IS BT simulation training of gynecologic malignancies and used in resident training and education sessions. (Source: Brachytherapy)
Source: Brachytherapy - May 1, 2021 Category: Cancer & Oncology Authors: Jay Shiao, Andrew Santoso, Kelly Stuhr, Stephanie Bennett, Douglas Holt, Tyler Robin, Christine Fisher Tags: Scientific Session: GYN Proffered Papers I Wednesday, June 23, 2021 10:00 AM - 11:00 AM Source Type: research

PP02 Presentation Time: 10:10 AM
Purpose: 3D-printing has emerged as a promising tool for brachytherapy simulation, training, and research. In brachytherapy for cervix cancer, many patients have tumors or anatomy that do not conform to a standard blocking template for needle alignment. In this pilot study, we sought to create a 3D-printed device that provided customized needle alignment for a patient and developed a 3D-printed mold and anatomical “phantom” model based on a patient CT scan to test the device. (Source: Brachytherapy)
Source: Brachytherapy - May 1, 2021 Category: Cancer & Oncology Authors: Destie Provenzano, Hamid Aghdam, GIzem Cifter, Sharad Goyal, Murray Loew, Yuan James Rao Source Type: research

PP03 Presentation Time: 10:20 AM
Purpose: The procedure of Intracavitary Brachytherapy (ICBT) involves use of spinal anesthesia and invasive procedure leading to anxiety among the patients. Music therapy (MT) has been established as an excellent measure to alleviate anxiety; however, the role is scarcely employed. This randomized study evaluates the impact of MT on anxiety and distress during the procedure of ICBT in cervical malignancies. (Source: Brachytherapy)
Source: Brachytherapy - May 1, 2021 Category: Cancer & Oncology Authors: Vibhay Pareek, Mansi Barthwal, Pritee Patil, Aman Sharma, Supriya Mallick, Dn Sharma Source Type: research

PP04 Presentation Time: 10:30 AM
In this study, we utilized the Monte Carlo (MC) simulations to design a new DMBT VC applicator to address the lack of dose coverage at the VC apex due to anisotropy effect and to provide directional modulation for coverage of legions that cannot be covered using the common VC applicators at the very critical region of the vaginal cuff. (Source: Brachytherapy)
Source: Brachytherapy - May 1, 2021 Category: Cancer & Oncology Authors: Moeen Meftahi, Emma Fields, William Song Source Type: research

PP05 Presentation Time: 10:40 AM
Purpose: Over 65,000 women were diagnosed with endometrial cancer (EC) in 2020. Standard treatment is TAH/BSO with radiation therapy (RT) and chemotherapy given based on risk factors. These can cause significant changes in the vagina, including shortening, narrowing, loss of elasticity, atrophy, and dryness. These complications are not life threatening, but can affect a woman's physical, psychological, and social functioning. Adjuvant vaginal dilator use is often advised, but there are currently inconsistent recommendations on use and no prospective data to support its efficacy. (Source: Brachytherapy)
Source: Brachytherapy - May 1, 2021 Category: Cancer & Oncology Authors: Bridget A. Quinn, Xiaoyan Deng, Stephanie A. Sullivan, Dipankar Bandyopadhyay, Emma C. Fields Source Type: research

PP06 Presentation Time: 10:50 AM
Purpose: It is well established in cervical brachytherapy that the addition of interstitial (IS) needles to intra-cavitary (IC) applicators can significantly enhance dosimetry by improving target coverage without increasing normal tissues doses. Accurate placement of interstitial needles requires significant skill and imaging guidance proficiency, thereby limiting the benefits to a subset of practitioners and patients. Available commercial combined IC/IS applicators restrict the available needle positions to often unsatisfactory locations for optimized dosimetry. (Source: Brachytherapy)
Source: Brachytherapy - May 1, 2021 Category: Cancer & Oncology Authors: Eric Simiele, Thomas Niedermayr, Elizabeth Kidd Source Type: research

PP07 Presentation Time: 11:00 AM
Purpose: Pd-103 has several potential advantages over I-125. Its shorter half-life may preferentially target tissues with lower alpha/beta ratios such as prostate cancer, while its lower energy results in greater dose heterogeneity. We utilized a large multi-institutional and multi-national database to compare clinical and biochemical failures between isotopes. (Source: Brachytherapy)
Source: Brachytherapy - May 1, 2021 Category: Cancer & Oncology Authors: Chad Tang, Jeremiah Sanders, Howard Thames, Juanita Crook, Pierre Blanchard, Jay Ciezki, Mira Keyes, Gregory Merrick, Charles Catton, Francis Sullivan, Richard Stock, Henry Mok, Jeremy Millar, Brian Moran, Michael Zelefsky, Steven Frank Tags: Scientific Session: Prostate Proffered Papers I Wednesday, June 23, 2021 11:00 AM - 12:00 PM Source Type: research

PP08 Presentation Time: 11:10 AM
This study aimed to determine the influence of hydrogel rectal spacer placement (HSP) on late rectal toxicity outcomes in prostate cancer patients treated with low dose rate (LDR) brachytherapy with or without supplemental external beam radiotherapy (EBRT). (Source: Brachytherapy)
Source: Brachytherapy - May 1, 2021 Category: Cancer & Oncology Authors: Michael J. Zelefsky, Achiraya Teyateeti, Craig Grossman, Megan Fiasconaro, Margaret Hopkins, Sean McBride, Daniel Gorovets, Daniel Shasha, Gilad Cohen, David Lesser, Zhigang Zhang, Antonio Damato, Marisa Kollmeier Source Type: research

PP09 Presentation Time: 11:20 AM
This study aimed to evaluate outcomes associated with a single-fraction high-dose-rate (HDR) brachytherapy boost combined with five-fraction stereotactic body radiation therapy (SBRT) for patients with unfavorable intermediate- or high-risk prostate cancer. (Source: Brachytherapy)
Source: Brachytherapy - May 1, 2021 Category: Cancer & Oncology Authors: Daniel Gorovets, Margaret Hopkins, Assaf Moore, Arrun Goel, Marisa Kollmeier, Daniel Shasha, Victoria Brennan, Sean McBride, Gilad Cohen, Antonio Damato, Michael J. Zelefsky Source Type: research

PP11 Presentation Time: 11:30 AM
Purpose: High dose rate (HDR) brachytherapy as primary therapy (monotherapy) is a standard National Comprehensive Cancer Network (NCCN) endorsed treatment option for patients with localized prostate cancer. Most data to date are limited to single institution experiences. Accordingly, we sought to systematically review rates of biochemical recurrence-free survival (bRFS) and toxicity associated with HDR monotherapy. (Source: Brachytherapy)
Source: Brachytherapy - May 1, 2021 Category: Cancer & Oncology Authors: Eric Anderson, Sungjin Kim, Howard Sandler, Mitchell Kamrava Source Type: research

PP10 Presentation Time: 11:40 AM
Purpose: We aimed to compare HDR brachytherapy alone to HDR brachytherapy as a boost for treatment of unfavorable intermediate risk prostate cancer. (Source: Brachytherapy)
Source: Brachytherapy - May 1, 2021 Category: Cancer & Oncology Authors: Eric Yu Lin, Fang-I Chu, Alan Lee, Albert J. Chang Source Type: research

PP12 Presentation Time: 11:50 AM
Purpose: To analyze long-term results of protocol-based ultrasound-guided salvage pulsed-dose rate brachytherapy in locally recurrent prostate cancer following previous radiation therapy. (Source: Brachytherapy)
Source: Brachytherapy - May 1, 2021 Category: Cancer & Oncology Authors: Vratislav Strnad, Nicole Sch önle, MIchael Lotter, Stephan Kreppner, Rainer Fietkau Source Type: research

PP13 Presentation Time: 3:30 PM
Purpose: The immunologic effects of radiation (RT) are influenced by RT dose and each may be optimized over a unique dose range. We hypothesized that a heterogeneous dose of RT might thereby optimally engage multiple immune pathways and allow for greater immune activation compared to homogenous RT dose. We used brachytherapy (BT) to deliver a heterogeneous RT dose within a single tumor and we compared the relative capacities of BT and homogenous dose external beam radiotherapy (EBRT) to enhance the anti-tumor immune response in combination with immune checkpoint inhibition (ICI). (Source: Brachytherapy)
Source: Brachytherapy - May 1, 2021 Category: Cancer & Oncology Authors: Justin Charles Jagodinsky, Ishan Chakravarty, Wonjong J. Jin, Raghava N. Sriramaneni, Paul A. Clark, Sarah E. Emma, Ian S. Arthur, Keng-Hsueh S. Lan, Rupak K. Das, Jessica R. Miller, Zachary S. Morris Tags: Scientific Session: Miscellaneous Proffered Papers I Wednesday, June 23, 2021 3:30 PM - 4:30 PM Source Type: research

PP14 Presentation Time: 3:39 PM
Purpose: Squamous cell carcinoma of the nasal vestibule is a rare tumor. It is usually diagnosed in Wang T1-T2 stage due to its readily visible location. Primary radiotherapy is often the preferred treatment for preservation of cosmesis and nasal function. Another important consideration in treatment of this tumor is avoiding mutilating salvage nose amputations. However, due to practice variation and lack of comparative trials, there is no consensus on preference for brachytherapy or external beam radiotherapy. (Source: Brachytherapy)
Source: Brachytherapy - May 1, 2021 Category: Cancer & Oncology Authors: Michal Czerwinski, Peter Jansen, Ellen Zwijnenburg, Abrahim Al-Mamgani, Marije Vergeer, Johannes Langendijk, Frederik Wesseling, Johannes Kaanders, Cornelia Verhoef Source Type: research

PP15 Presentation Time: 3:48 PM
Background: Recurrent GBM (rGBM) is a diffuse disease, and local therapy alone does not routinely provide durable local control (LC) or prolong overall survival (OS). Hypothesizing resection (R) plus immediate radiation (RT) may achieve durable LC and secondarily improve OS by permitting time for subsequent potentially effective but biologically slower treatments to have an impact, we prospectively evaluated R combined with a novel brain brachytherapy device utilizing Cs-131 embedded in bioresorbable collagen tiles with the intention of combining R and immediate onset radiation surgically targeted radiation therapy (STaRT)...
Source: Brachytherapy - May 1, 2021 Category: Cancer & Oncology Authors: David Brachman, Peter Nakaji, Kris Smith, Theresa Thomas, Christopher Dardis, Garrick Wallstrom, Dilini Pinnaduwage, Leland Rogers, Emad Yousssef Source Type: research

PP16 Presentation Time: 3:57 PM
Purpose: Deposition of plaque along the walls of a coronary artery leads to narrowed vessels (stenosis) and is one of the main causes of death in developed countries. Percutaneous transluminal coronary angioplasty is a treatment modality used to open the blocked arteries allowing unobstructed blood flow to the myocardium. However, the treated vessel may become narrow again. The event is referred to as restenosis. Restenosis can be prevented with the advent of bare metal stents; however, expanding a stent inside a vessel will subject the artery to high stresses that can injure the tissue, potentially leading to in-stent res...
Source: Brachytherapy - May 1, 2021 Category: Cancer & Oncology Authors: Kiarash Ghasemi Source Type: research

PP17 Presentation Time: 4:06 PM
Purpose: The Radiation Oncology Alternative Payment Model (RO Model) will test prospective episode-based payments for radiotherapy episodes for 16 common disease sites. Most radiation modalities, including brachytherapy monotherapy, combination modality therapy, external beam radiation therapy and proton therapy, will be included in the model. We created an automated analytics platform to calculate the impact of the RO Model vs historical fee-for-service episode reimbursements for brachytherapy treatments within five community oncology practices for prostate, uterine, and cervical cancer. (Source: Brachytherapy)
Source: Brachytherapy - May 1, 2021 Category: Cancer & Oncology Authors: Nikhil G. Thaker, Rehman Meghani, Cassandra Wilson, Jody Garey, Philip Nelson, Gautam H. Thaker, Chirag Shah, Peter Orio, Catheryn M. Yashar, Vivek Kavadi Source Type: research

PP18 Presentation Time: 4:15 PM
Purpose: To estimate the impact of the finalized Radiation Oncology Alternative Payment Model (RO-APM) relative to current Medicare Fee-For-Service payments upon prostate brachytherapy technical reimbursement in the hospital outpatient practice setting. (Source: Brachytherapy)
Source: Brachytherapy - May 1, 2021 Category: Cancer & Oncology Authors: Constantine Anastasios Mantz Source Type: research